Strategic collaborations BIOASTER leads multi-stakeholder projects with academia, startups, SMEs and industry players across infectious diseases and microbiology, presenting opportunities to position a partner as a preferred collaboration or co-development sponsor in AMR, vaccine safety, and rapid diagnostics.

AMR focal demand A core emphasis on antimicrobial resistance, diagnostics, and therapeutics translates to sales opportunities for partners offering antimicrobial discovery platforms, diagnostic assays, and related regulatory support, as well as services to accelerate from research to market.

Strategic partnerships Recent collaborations with Qiagen, Cynbiose, PharmaLex and NIH signal openness to distribution, platform integration, and go-to-market support services; potential for channel partnerships, technology licensing, and joint ventures.

Global capability With over 100 employees including 80 scientists from 16 countries and operations in Lyon and Paris, BIOASTER offers international research capacity and a diverse talent pool ideal for multinational consortia, translational programs, and cross-border funding proposals.

Funding and growth Revenue under one million and a strong institute network across France provide a pathway for grant-backed projects, public-private funding opportunities, and early-stage collaboration deals with large CROs and diagnostic developers seeking access to antimicrobial and diagnostic innovations.